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Portopulmonary hypertension (PPH) represents an uncommon form of pulmonary arterial hypertension
(PAH) associated with portal hypertension and cirrhosis. PPH is a severe disease with a poor short-term
prognosis, with a possibility of liver transplantation only for patients with mild to moderate PAH.
Patients with PAH could be candidates for speciﬁc vasodilator-based treatment, the choice of which
being guided by their toxicity proﬁle. We report here the case of a 46-year-old woman with a cirrhosis
(Child-Pugh C) complicated by a severe PPH (mean pulmonary arterial pressure: 49 mmHg, pulmonary
vascular resistance: 688 dynes, right ventricular dysfunction), with NYHA class III dyspnea and an altered
6-min walk distance (6MWD). Treatment with sildenaﬁl (20 mg t.i.d) was started. In the ﬁrst 6 months,
a functional improvement was indicated by dyspnea assessed as class II, an increased distance at the
6MWD (375 m vs. 250 mwithout oxygen desaturation), and a normalization of right ventricular function.
After one year of therapy, the beneﬁts were maintained (6MWD: 465 m) and transthoracic echocardi-
ography showed a normalization of pulmonary arterial pressures. Sildenaﬁl treatment was well toler-
ated. At two years, haemodynamic values measured by right heart catheterization were similar to the
pre-treatment values, while clinical and functional parameters remained improved. At our knowledge,
this is the ﬁrst case delineating the long-term functional beneﬁt of sildenaﬁl monotherapy, making this
drug a therapeutic option in patients with PPH and cirrhosis, the usefulness of which in the waiting
period for liver transplantation needs to be evaluated.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Pulmonary arterial hypertension (PAH) is a severe and rare
disease characterized by a progressive increase of pulmonary
vascular resistance (PVR) leading to right ventricular (RV) failure
and death.1 The current admitted classiﬁcation of PAH in the adult
includes idiopathic PAH, familial PAH and a third group of PAH
associated with various pathologies, including portal hypertension.
Portopulmonary hypertension (PPH) is deﬁned by the associa-
tion of PAH and portal hypertension, with or without hepatic
disease.2 According to the PAH French national registry, PPH is the
third-most common type of PAH.3 Like for idiopathic PAH, diag-
nosis of PPH is based on haemodynamic values obtained by right
heart catheterization (RHC). Diagnosis criteria include a meanx: þ33 4 91 74 45 90.
(S. Boniface).
rved.pulmonary artery pressure (mPAP)> 25 mmHg at rest or> 30
mmHg with exercise, a mean pulmonary artery occlusion pressure
(mPAOP)< 15 mmHg and a pulmonary vascular resistance
(PVR)> 240 dyn.s.cm5.1
PPH is associated with a short-term poor prognosis, with
a median survival of 6 months and a 5 year-survival of 30%.2 Liver
transplantation (LT) is the only curative treatment of PPH provided
that PAH is moderate.1,2 Drug-based treatments have not been
thoroughly studied, so that the recommended algorithm is based
on that developed for PAH including background therapy and
general measures, and also more speciﬁc treatments.1 In the
absence of response to vasoreactivity test during right heart cath-
eterization, which is observed in almost all patients with PPH,3
treatment by prostacyclins or oral sildenaﬁl may be considered as
possible options,1 with the objectives of correcting haemodynamic
parameters to make LT feasible, and also as a post-operative cure
for PPH.4 Oral endothelin antagonists were not retained in inter-
national guidelines for the treatment of PPH because of potential
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this class of drugs.1 To date, little is known about the efﬁciency of
such therapies in patients with PPH due to the lack of clinical
studies. In this context, case reports appear to be fruitful to provide
additional information on clinical, haemodynamic and safety data
in speciﬁc situations not covered by randomized trials.
2. Case report
A 46-year-old woman who had experienced hepatorenal
syndrome associated with cardiac decompensation after inguinal
surgery was referred to our hospital with a dyspnea class III
(NYHA). Cirrhosis Child C had been diagnosed the year before as
well as a progressive dyspnea. At the time of admission, the patient
presented a portal hypertension associated with liver spleno-
megaly and esophageal varices of grade I. PAH was suspected and
further conﬁrmed by transthoracic echocardiography and RHC.
Systolic pulmonary arterial pressure (sPAP), mPAP and PVR were
75–80 mmHg, 49 mmHg and 688 dyn.s.cm5, respectively, and
were associated with RV dysfunction (right atrium area:¼ 27 cm2).
Distance during 6 min walk test (6MWD) was 250 m, with oxygen
desaturation reaching 91% at the end of 6MWD. A diagnosis of
severe PPH associated with cirrhosis Child C was then established.
Clinical and haemodynamic values are presented in Table 1. While
the context of hepatorenal syndrome and liver parameters would
havemade the patient candidate for LT, the latter was considered as
contraindicated because of severe PAH. Pharmacological optionwas
then retained. The patient did not respond to vasoreactivity test
with NO performed during RHC, and conventional therapy was
then excluded. In a context of liver failure and risk of hyper-
splenism, sildenaﬁl was considered as the most appropriate
therapy in terms of beneﬁt and safety. The patient revealed an
active smoking status (30 pack-years) at the time of PPH diagnosis.
Sildenaﬁl treatment was started at the usual dose of 20 mg t.i.d.
in associationwith nasal oxygenation as well as B1-B6-B9 vitamins,
diuretics, cholestyramine and esomeprazole. Evolutions of respi-
ratory and cardiac parameters are shown in Table 1. Improvements
were observed within six months in terms of functional class (from
III to II), exercise capacity without desaturation (6MWD from 250 to
375 m), which led to stop oxygenation. Haemodynamic normali-
zation was measured but, unfortunately, the patient refused RHC.
This trend was maintained during the next months, with sPAPTable 1
Clinical, functional and haemodynamic evolution over the 2 year period of treatment w
Date (mo/yr) 04/2006 11/2006 04/2007
Clinical parameters
Dyspnea (NYHA class) III II II
PO2/PCO2/pH 84/26/7.43 90/28/7.40 91/27/7.4
6MWD (m) (SaO2 min) 250 (94–91%) 375 (98%) 410 (98–9
Transthoracic Doppler-Echocardiography
PAPs (mmHg) Function 75–80 RV
dysfunction
60 RV normal 45 RV nor
Right heart catheterization
s/d/mPAP (mmHg) 76/34/49 RHC refused –
mRAP/PAOP (mmHg) 13/9 – –
PVR (UWood) 8.6b – –
PACWP (mmHg) – – –
CO (L/min)/ CI (L/min.m2) 4.6/3.2 – –
Treatment
sildenaﬁlaþO2 sildenaﬁlþO2 sildenaﬁl,
Abbreviations: 6MWD, 6-min walk distance; RV, right ventricle; s/d/mPAP, systolic/dia
mean pulmonary artery occlusion pressure; PVR, pulmonary vascular resistance; PACWP
a sildenaﬁl was started on April 2006 and maintained over the 2 years.
b 866 dynes.s.cm-5.reaching 45 mmHg after 1 year of sildenaﬁl, a normalization of
haemodynamics (mPAP¼ 30mmHg) and a decrease in right atrium
area (21 cm2). During the same period, liver function parameters
remained stable. After one year, the patient accepted to stop
smoking.
After two years of treatment with sildenaﬁl, RHC was per-
formed, which showed haemodynamic values close to those
measured at the beginning of the treatment (Table 1). However,
functional class of dyspnea remained improved as well as 6MWD
value which was further increased (475 m without desaturation in
O2). Treatment by sildenaﬁl was well tolerated by the patient with
no adverse event related to the drug during two years, and was
then continued.
3. Discussion
PPH is expected to occur in 0.5–1% of patients with cirrhosis5,6
and corresponds to 10% of PAHwhose it represents the third cause.3
PPH includes both portal hypertension and pulmonary hyperten-
sion so that the management of the disease is complicated by the
impact of one type of hypertension on the usual strategy of the
other. Thus, LT is contraindicated in patients with PAH because of
the risk due to haemodynamic alterations (especially with PAP 35
mmHg and PVR 250 dyn.s.cm5), and liver failure may limit the
use of speciﬁc treatments recommended in PAH.1,2 Concerning PAH
NYHA class III, international guidelines proposed by the task force
on diagnosis and treatment of PAH of the European Society of
Cardiology and Pneumology recommend considering oral calcium
channel blockers in patients responding to vasoreactivity test.1
However, only 10% of patients with PAH are expected to respond to
the test, and they are less than 2% when PAH is associated with
portal hypertension.3 In that context, speciﬁc treatments including
prostanoid analogs, endothelin receptor agonists (ERA) and phos-
phodiesterase type 5 (PDE5) inhibitors are recommended.7
The challenge of severe PPH management is then to make
haemodynamic values compatible with LT and to maintain therapy
after transplantation, in taking into account the tolerance proﬁle of
the treatment in patients with liver failure. Due to its potential for
hepatotoxicity and the absence of long-term study in patients with
liver disease, oral bosentan, an ERA approved in PAH, does not
appear as a good candidate in the treatment of PPH with Child B or
C cirrhosis.1 While small studies have shown response to i.v.ith sildenaﬁl.
10/2007 12/2007 05/2008
I–II II II
4 90/30/7.43 97/27/7.41 96/28/7.40
6%) 465 (98–94%) – 475 (94%)
mal – 60 minimal TI 60 minimal TI
– – 83/24/54
– – 13/9
– – 8.1
– – 15
– – 4.8/3.0
smoking cessation sildenaﬁl sildenaﬁl sildenaﬁl
stolic/mean pulmonary arterial pressure; mRAP, mean right atrial pressure; PAOP,
, pulmonary artery capillary wedge pressure; CO, cardiac output; CI, cardiac index.
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possible risk of ascites and splenomegaly makes the treatment be
considered cautiously.10 Among the treatments recommended in
the management of class III PAH, only inhibitors of PDE5 are char-
acterized by a beneﬁt/risk ratio adapted to PPH with Child
C cirrhosis.11–13
PDE5 inhibitors have been developed as novel therapies in
pulmonary hypertension due to the role of PDE5 in the changes of
NOpathways occurring during PAH.14 Basedon the results of SUPER-
1 double-blind placebo controlled trial performed inmore than 200
patients with PAH,11 sildenaﬁl was the ﬁrst PDE5 inhibitor to be
approved in the treatment of PAH in NYHA class III.7 The SUPER-1
study showed that 1 year treatment by sildenaﬁl improved func-
tional class; exercise capacity and haemodynamics,11 making sil-
denaﬁl be recommended for the treatmentof class II/III PAHwith the
same grade of evidence (A) as prostacyclin i.v. or ERAs.7
One study with sildenaﬁl12 and several case series or
reports13,15–20 support the beneﬁt of PDE5-based therapy in
patients with PPH, either used as a single agent or in combined
therapy. The study by Reichenberger et al.,12 including 13 patients
with severe portopulmonary hypertension, showed signiﬁcant
clinical, functional and haemodynamic improvements in patients
within 3 months of treatment with sildenaﬁl 50 mg t.i.d, as single
therapy or in combination with the inhaled prostanoid analog ilo-
prost. Beneﬁts on functional class, exercise capacity (6MWD), as
well as pro-BNP levels and RVP were sustained over 12 months.
While being limited by the heterogeneous etiology of liver disease
and the absence of Child C patients in the study (except one), the
improvements observed and the absence of signiﬁcant toxicity
support the role of sildenaﬁl as an effective agent in PPHwhen used
as a monotherapy. In their study, mPAP was signiﬁcantly decreased
after 3 months of monotherapy or combined therapy, but de
difference did not longer reach statistical signiﬁcance after 12
months. Due to the severity of PPH, the sustained efﬁciency of sil-
denaﬁl alone over time has been questioned,4 particularly con-
cerning the effect on haemodynamic values. More recently,
a retrospective observation of ten PPH obese patients treated with
sildenaﬁl monotherapy 25–50 mg t.i.d. showed stabilization of
haemodynamics and improvement of functional class within 12
months coupled with a good safety proﬁle, which made three
patients eligible for liver transplantation.13 In this study, an increase
in the 6MWD was observed, but which did not reach statistical
signiﬁcance. The mean value was 26 82 m at 1 year, which is
lower than that measured in our patient, even though the upper
value is considered. Furthermore, the fact that some patients in this
retrospective study were treated with various sildenaﬁl doses,
including higher doses than that commonly recommended
(50 mg t.i.d), makes the comparison difﬁcult. A recent case report in
a patient with severe PPH suggested the beneﬁt of three drug-
based combined therapy (including inhaled prostanoid, sildenaﬁl
and bosentan) as pretransplantation treatment.20 However, while
the combination of treatments from different pharmacological
classes recommended (e.g. prostanoid analogs, ERAs, inhibitors of
PDE5) appears attractive in severe or complicated PAH ,7,21 this
strategy is limited by toxicity proﬁles over a long-term period,
particularly in patients for whom transplantation is contraindicated
and/or delayed. This is probably the reason why the case reports
concerning patients with PPH mainly considered sildenaﬁl as
a single agent.
To our knowledge, our case is the ﬁrst one reporting long-term
beneﬁts and safety of sildenaﬁl as a monotherapy at the dose of
20 mg t.i.d. in a patient with PPH. The dose used corresponds to that
approved for the treatment of PAH, and is lower than that used in
previous case reports and studies (50–100 mg t.i.d). Our results
showed rapid functional and haemodynamic beneﬁts, which weresustained over 1 year with sildenaﬁl as a single agent. However,
while exercise capacity improvement was maintained after 2 years,
haemodynamic values assessed by RHC were close to baseline
values.
The functional beneﬁt could not have been due to smoking
cessation, as the latter occurred after 1 year of treatment, but most
likely reﬂects a possible discrepancy between clinical and haemo-
dynamicdata overa long-termperiod. The admittedhaemodynamic
criteria of therapeutic evaluation in PAH are cardiac index andmean
right atrial pressure. Sustained normalization in PAH appears to be
rare,14 especially for PPHassociatedwith complicated factors suchas
portal hypertension and related phenomena like splenomegaly.
Furthermore, the only curative treatment remains cardiac
tranplantation. Exercise capacity (assessed by 6MWD) is also awell-
known parameter of disease severity and evolution, as it is consid-
ered as both reproducible and representative of daily-life activities
and cardiopulmonary exercise capacity.1,7,14,22,23 Furthermore, the
decrease in this parameter represents a risk factor of death, inde-
pendently associated with PAH.14 In our patient, the maintained
elevated 6MWDvalue, coupledwith oxygen interruption, is in favor
of a substantial clinical beneﬁt of the treatment by sildenaﬁl.
According to its good tolerance proﬁle reported in patients with
PAH,11,24 sildenaﬁl was well tolerated over the 2 year period of
treatment, and no liver toxicity or negative impact on portal
hypertension was noted. The absence of hepatotoxicty in patients
with liver disease is consistent with the tolerance of sildenaﬁl
demonstrated in alcohol-fed animal models25 and clinical data in
patients treated for PPH.12 However, a possible increase in portal
pressure by sildenaﬁl has been shown in cirrhotic animal models,26
so that a risk of exacerbation of portal hypertension in cirrhotic
patients, as reported in one patient with PAH associated with
severe cirrhosis,17 may not be excluded.
In conclusion, we report the long-term beneﬁt of sildenaﬁl as
a single agent and at a usual dose in a patient with severe PPH for
whom poor speciﬁc therapy options were available. The rapid
haemodynamic effect and the persistence of long-term clinical and
functional beneﬁts, coupled with the absence of adverse events,
suggest that sildenaﬁl can be considered as a feasible and efﬁcient
option during waiting period for LT, which should be assessed in
further clinical studies.
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